Is Insulin-like Growth Factor-1 (IGF‑1) useful for assessing Growth Hormone (GH) signaling and overall anabolic status?

IGF-1 is Useful for Assessing GH Signaling and Anabolic Status

Yes, IGF-1 is a reliable and clinically useful marker for assessing GH signaling and overall anabolic status, though interpretation requires careful attention to age, sex, pubertal stage, and confounding clinical conditions.

Primary Utility for GH Signaling Assessment

Elevated age-adjusted, sex-adjusted, and Tanner stage-matched serum IGF-1 concentration is a reliable marker for GH excess 1. The 2024 Nature Reviews Endocrinology consensus guidelines provide a strong recommendation (moderate-quality evidence) that diagnosis of GH excess is supported by elevated IGF-1 relative to appropriate reference ranges 1.

IGF-1 offers several advantages over direct GH measurement:

• IGF-1 has a longer half-life than GH, making it less susceptible to pulsatile fluctuations and providing a more stable assessment of GH secretory status 2
• A single random plasma IGF-1 level provides an accurate reflection of GH secretion in most circumstances 3
• IGF-1 correlates linearly with GH levels up to 4 μg/l, though it plateaus at approximately 10 μg/l in states of severe GH excess 1

Utility for Anabolic Status Assessment

IGF-1 serves as a valuable biomarker of nutritional and anabolic status, as its production signals the availability of nutrients needed for anabolic actions 4. Key applications include:

• Nutritional status assessment: IGF-1 concentrations fall in malnutrition and respond promptly to refeeding 4
• Monitoring nutritional support: IGF-1 can provide information on prognosis and effectiveness of nutritional interventions 4
• Overall catabolic or anabolic processes: Decreasing or increasing plasma IGF-1 levels are associated with catabolic or anabolic states, respectively 3

Critical Interpretation Caveats

Age and Developmental Considerations

IGF-1 interpretation must account for age-related and pubertal stage-matched reference ranges 1. Marginal or mild elevation during adolescence, particularly during peak growth spurt, requires cautious interpretation 1.

Conditions Causing Falsely Low IGF-1 (Despite Normal/High GH)

IGF-1 values may be falsely normal or low in patients with GH-secreting adenomas when concurrent conditions exist 1:

• Severe hypothyroidism
• Malnutrition or severe infection
• Oral estrogen use (reduces hepatic IGF-1 generation)

Conditions Causing Falsely Elevated IGF-1 (Without GH Excess)

IGF-1 may be falsely elevated in patients without GH excess in the following conditions 1:

• Poorly controlled diabetes mellitus
• Hepatic and/or renal failure
• Chronic kidney disease 5
• Dopamine agonist therapy 5

Assay-Related Limitations

Inter-assay variability is significant, requiring establishment of local Tanner stage-matched, sex-matched, and age-matched normal ranges for each specific IGF-1 assay 1. The presence of IGF-binding proteins (IGFBPs) can interfere with immunoassays, as approximately 98% of circulating IGF-1 is bound to these carrier proteins 6, 2.

Clinical Algorithm for IGF-1 Interpretation

For Suspected GH Excess:

1. Measure IGF-1 with age-, sex-, and Tanner stage-appropriate reference ranges 1
2. If elevated, interpret within clinical context: height velocity, pubertal stage, bone age 1
3. Both GH and IGF-1 should be monitored at baseline and during follow-up in confirmed GH excess 1
4. Rule out confounding factors: diabetes control, renal/hepatic function, medication use 1, 5

For Suspected GH Deficiency:

IGF-1 has utility as a screening test in children and young adults but cannot be used as a stand-alone diagnostic test 7. In GH deficiency states, non-GH-related factors (nutrition, thyroid status, cortisol, sex steroids) predominate, reducing diagnostic specificity 7, 8.

For Nutritional/Anabolic Assessment:

1. Measure IGF-1 alongside acute-phase reactants (CRP) to distinguish nutritional effects from inflammatory suppression 4
2. Consider thyroid function, cortisol, and sex steroid status, as these hormones regulate IGF-1 independent of nutrition 3, 7
3. Serial measurements are more informative than single values for monitoring nutritional interventions 4

Monitoring During GH Therapy

IGF-1 monitoring at least twice yearly is recommended during GH therapy, with dosing adjusted to keep IGF-1 in the physiologic range 1. This approach:

• Informs adherence to therapy 8
• Provides a safety reference to avoid over-dosing 8
• Helps predict growth response 8

Common Pitfalls to Avoid

• Do not interpret IGF-1 in isolation: Always consider clinical phenotype, growth parameters, and potential confounding conditions 1
• Do not use a single elevated IGF-1 to diagnose acromegaly in adolescents: Physiologic elevation occurs during puberty 1
• Do not rely on IGF-1 alone for GH deficiency diagnosis: Provocative GH testing remains necessary in most cases 7
• Do not ignore assay-specific reference ranges: Significant inter-assay variability exists 1, 2
• Do not overlook the acute-phase response: Inflammation suppresses IGF-1 independent of GH or nutritional status 4